In conclusion, baseline cardiovascular diseases are common in patients treated with strontium ranelate, with more than half of strontium ranelate users being current

users of antiplatelet drugs or having a history of cerebrovascular disease, peripheral vascular disease or myocardial infarction. Moreover, this observational study shows an increased confounder-adjusted mortality risk in patients treated with strontium ranelate compared with other osteoporosis drugs.

Autor: B. Abrahamsen, E. L. Grove, P. Vestergaard

Leave a Reply

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

  • 2 × cinco =